Cediranib: a VEGF receptor tyrosine kinase inhibitor

Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study

(2012) Peter Mulders et al.   EUROPEAN JOURNAL OF CANCER

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

(2011) F A Raja et al.   BRITISH JOURNAL OF CANCER

Sorafenib for the management of advanced renal cell carcinoma

(2011) Bernard Escudier   Expert Review of Anticancer Therapy

A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

(2010) Claire L. Mitchell et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cediranib/AZD2171 Inhibits Bone and Brain Metastasis in a Preclinical Model of Advanced Prostate Cancer

(2010) J. J. Yin et al.   CANCER RESEARCH

Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

(2010) E. S. Robinson et al.   Clinical Journal of the American Society of Nephrology

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097)

(2010) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III

(2009) Jane D. Robertson et al.   Clinical Colorectal Cancer

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

(2009) Ursula A. Matulonis et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

(2009) Glenwood D. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Control of Lymphatic Metastasis

(2008) Marc G. Achen et al.   Annals of the New York Academy of Sciences

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

(2008) Glenwood Goss et al.   EUROPEAN JOURNAL OF CANCER